Adverse Factors in Diffuse Large B-Cell Lymphoma

Researchers of a study identified several potential adverse factors in diffuse Large B- cell lymphoma (DLBCL). The study was published in Leukemia Research. 

In this study, researchers sought to elucidate the clinical, inflammatory, and immunohistochemical features of a cohort of 73 patients with DLBCL who were treated with chemoimmunotherapy between 2010 and 2015. They used International Prognostic Index (IPI) and National Comprehensive Cancer Network (NCCN)-IPI scores to assess complete response (CR). They used Cox proportional-hazard regression to analyze progression-free survival (PFS) and overall survival (OS).

According to the results, both IPI and NCCN-IPI scores were statistically associated with PFS and OS. Also, the researchers showed that neutrophil/lymphocyte ratio (NLR) ≥ 4 was linked with lower odds of CR (odds ratio, 0.19; P=0.007), worse PFS (hazard ratio [HR], 2.67; P=0.02), and worse OS (HR, 2.77; P=0.02). The researchers noted that albumin <3.5 g/dL was associated with worse OS when adjusted for the NCCN-IPI score (HR, 2.96; P=0.04).

“Our study identified NLR ≥4 and albumin <3.5 g/dL as potential adverse factors in [patients with] DLBCL and could add to the prognostic value of the IPI or the NCCN-IPI scores,” the researchers concluded.